TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SynAct Pharma AB ( (SE:SYNACT) ) has issued an update.
SynAct Pharma AB has announced an Extraordinary General Meeting scheduled for November 27, 2025, in Stockholm, Sweden. The meeting will address several key resolutions, including the introduction of an employee share option program (ESOP 2025), a directed issue of warrants, and authorization for the acquisition and transfer of own shares. These initiatives are likely aimed at enhancing employee engagement and optimizing the company’s capital structure, potentially impacting shareholder value and market positioning.
More about SynAct Pharma AB
SynAct Pharma AB operates in the pharmaceutical industry, focusing on developing innovative therapies for inflammatory diseases. The company is known for its research and development of treatments that aim to modulate the immune system to address chronic inflammation.
Average Trading Volume: 177,932
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.15B
See more insights into SYNACT stock on TipRanks’ Stock Analysis page.